Pitavastatin

Generic Name: Pitavastatin

Brand Names: Livalo, Zypitamag

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₄FNO_₄

CAS Number: 147511-69-1

Unique Ingredient Identifier: M5681Q5F9P

Background: Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competiti...

Indication: 用于治疗高胆固醇症(高脂血症)、家族性高胆固醇症。

Associated Conditions: Apolipoprotein B increased, Elevation of serum triglyceride levels, Increases in serum total low-density lipoprotein (LDL), Increases in total cholesterol

Associated Therapies: -

Clinical Trials

Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia

Phase 4

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: pitavastatin
Drug: atorvastatin

First Posted Date: 2010-07-21

Last Posted Date: 2022-04-11

Lead Sponsor: JW Pharmaceutical

Target Recruit Count: 200

Registration Number: NCT01166633

Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia

Phase 4

Completed

Conditions: Hypercholesterolemia With Type2DM

Interventions: Drug: Atorvastatin
Drug: Pitavastatin

First Posted Date: 2009-04-28

Last Posted Date: 2019-09-17

Lead Sponsor: JW Pharmaceutical

Target Recruit Count: 161

Registration Number: NCT00889226

Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)

Phase 4

Completed

Conditions: Hypercholesterolemia
Coronary Artery Disease

Interventions: Drug: Pitavastatin
Drug: Atorvastatin

First Posted Date: 2009-03-16

Last Posted Date: 2013-10-14

Lead Sponsor: Kumamoto University

Target Recruit Count: 129

Registration Number: NCT00861861

Locations: 🇯🇵
Kumamoto University Graduate School of Medical Sciences Department of Cardiocascular Medicine, Kumamoto, Japan

Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)

Not Applicable

Terminated

Conditions: Cardiovascular Disease

Interventions: Drug: Pitavastatin

First Posted Date: 2009-02-18

Last Posted Date: 2021-08-30

Lead Sponsor: Chieko Hamada

Target Recruit Count: 905

Registration Number: NCT00846118

Locations: 🇯🇵
Division of Nephrology, Department of Internal Medicine, Juntendo Hospital, Tokyo, Japan

Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)

Phase 4

Withdrawn

Conditions: Percutaneous Coronary Intervention

Interventions: Drug: Pitavastatin

First Posted Date: 2008-11-06

Last Posted Date: 2012-03-30

Lead Sponsor: JW Pharmaceutical

Registration Number: NCT00786734

Locations: 🇰🇷
Catholic University of Korea Kangnam St. Mary's Hospital, Seoul, Korea, Republic of

Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers

Not Applicable

Completed

Conditions: Healthy Volunteers

Interventions: Drug: simvastatin
Drug: atorvastatin
Drug: pitavastatin

First Posted Date: 2008-07-16

Last Posted Date: 2011-09-07

Lead Sponsor: Hamamatsu University

Target Recruit Count: 11

Registration Number: NCT00716846

Locations: 🇯🇵
Hamamatsu University School of Medicine, Hamamatsu, Japan

Pitavastatin on Carotid Intima-media Thickness

Not Applicable

Conditions: Hyperlipidemia
Carotid Artery Diseases

Interventions: Drug: Pitavastatin

First Posted Date: 2008-07-09

Last Posted Date: 2009-09-10

Lead Sponsor: Kyoto Prefectural University of Medicine

Target Recruit Count: 300

Registration Number: NCT00711919

Locations: 🇯🇵
Ayabe City Hospital, Ayabe, Kyoto, Japan
🇯🇵
Tanabe Central Hospital, Kyotanabe, Kyoto, Japan
🇯🇵
Maizuru Kyosai Hospital, Maizuru, Kyoto, Japan

and more 15 locations

South Korean Pitavastatin Heart Failure Study

Phase 4

Completed

Conditions: Chronic Heart Failure

Interventions: Drug: pitavastatin
Drug: pravastatin

First Posted Date: 2008-06-19

Last Posted Date: 2014-05-14

Lead Sponsor: JW Pharmaceutical

Target Recruit Count: 70

Registration Number: NCT00701285

Locations: 🇰🇷
SEOUL St. Mary's Hospital, Seoul, Seocho-Ku, Korea, Republic of

Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

Phase 1

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: SCH 58235
Drug: pitavastatin

First Posted Date: 2008-04-07

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 18

Registration Number: NCT00653913

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

Phase 4

Completed

Conditions: Hypercholesterolemia
Metabolic Syndrome

Interventions: Behavioral: Lifestyle Modification
Drug: pitavastatin

First Posted Date: 2008-03-21

Last Posted Date: 2012-03-30

Lead Sponsor: JW Pharmaceutical

Target Recruit Count: 187

Registration Number: NCT00640276

Locations: 🇰🇷
Seoul National University Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of
🇰🇷
Hanyang Univ. Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy